# FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC

> **NCT05217069** · PHASE2 · COMPLETED · sponsor: **Ludwig-Maximilians - University of Munich** · enrollment: 57 (actual)

## Conditions studied

- Treatment Related Cancer

## Interventions

- **DRUG:** 5-FU
- **DRUG:** Folinic Acid
- **DRUG:** Irinotecan
- **DRUG:** Cetuximab
- **DRUG:** Avelumab

## Key facts

- **NCT ID:** NCT05217069
- **Lead sponsor:** Ludwig-Maximilians - University of Munich
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-27
- **Primary completion:** 2023-09-01
- **Final completion:** 2023-10-18
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2025-04-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05217069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05217069, "FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05217069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*